Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
CV Risk of White-Coat Hypertension
J Am Coll Cardiol; 2016 Nov; Franklin, Thijs, et al
White-coat hypertension (WCH) size is related to aging, not to cardiovascular risk, according to a recent study that performed age- and cohort-matching between 653 untreated individuals with WCH and 653 normotensive control individuals. Researchers found:
• Systolic white-coat-effect (WCE) increased by 3.6 mm Hg per 10-year increase in age, and was similar in low- and high-risk individuals with or without prior CVD events.
• Incidence of new CVD events was higher in 159 high-risk individuals with WCH vs 159 cohort- and age-matched high-risk normotensive individuals (aHR, 2.06) over a median 10.6-year follow-up.
• There was no significant increase in risk for 494 participants with low-risk WCH and age-matched low-risk normotensive participants.
• An association between WCH and incident CVD events was limited to older (≥60 years) high-risk WCH participants.
Citation: Franklin SS, Thijs L, Asayama K, et al. The cardiovascular risk of white-coat hypertension. J Am Coll Cardiol. 2016;68(19):2033-2043. doi:10.1016/j.jacc.2016.08.035.
1. Pickering TG, et al. Call to action on use and reimbursement for home blood pressure monitoring. A joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension. 2008;52:10-29.